Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread from where it first started to other places in the body (metastatic), and that has come back after a period of improvement (recurrent). It also studies the effects of salvage radiation therapy (sXRT) on prostate cancer and to see if radiation to the pelvis helps prevent prostate cancer from spreading elsewhere. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Androgen can cause the growth of prostate cells. ADT lowers the amount of androgen made by the body. This may help stop the growth of tumor cells that need androgen to grow. Androgen receptor pathway inhibitors work by blocking the effects of androgen to stop the growth and spread of tumor cells. sXRT is a targeted radiation treatment for the prostate, typically given when cancer possibly returns after surgery or radiation. Its goal is to destroy any tumor cells in the area. Giving SBRT alone with watchful waiting may be as effective in treating prostate cancer as giving SBRT together with ARPI and ADT and sXRT may be effective in treating prostate cancer and preventing it from spreading elsewhere.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Rak prostaty, który wrócił po leczeniu i rozprzestrzenił się na inne części ciała (5 lub mniej ognisk)
- •Wysoki poziom testosteronu we krwi (powyżej 100 ng/dL)
- •Zdolność do chodzenia i wykonywania codziennych czynności (stan sprawności 0-2)
- •Prawidłowe wyniki badań krwi: hemoglobina, białe krwinki, płytki krwi
- •Prawidłowa funkcja wątroby i nerek
- •Zgoda na udział w badaniu i pobieranie próbek krwi
✗ Disqualifies
- •Ciąża
- •Karmienie piersią
- •Zdolność do zajścia w ciążę
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 20, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (3)
Mayo Clinic in Arizona
Phoenix, United States
Mayo Clinic in Florida
Jacksonville, United States
Mayo Clinic in Rochester
Rochester, United States
Trial contact
Clinical Trials Referral Office
Cancer Center Clinical Trials
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/21/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.